Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias-Reference-Cited by-同舟云学术

Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias

Published:2018-11-20 Issue:2 Volume:83 Page:319-328
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Singh Renu, ,Mehrotra Shailly,Gopalakrishnan Mathangi^ORCID,Gojo Ivana,Karp Judith E.,Greer Jacqueline M.,Chen Alice,Piekarz Richard,Kiesel Brian F.,Gobburu Jogarao,Rudek Michelle A.,Beumer Jan H.

Funder

National Institutes of Health

Cancer Institute, University of Pittsburgh

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3731-4/fulltext.html

Reference29 articles.

1. Cheung-Ong K, Giaever G, Nislow C (2013) DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol 20(5):648–659

2. Tian H, Gao Z, Li H et al (2015) DNA damage response—a double-edged sword in cancer prevention and cancer therapy. Cancer Lett 358(1):8–16

3. Heitz F, Harter P, Ewald-Riegler N et al (2010) Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Expert Rev Anticancer Ther 10(7):1125–1136

4. De Vos M, Schreiber V, Dantzer F (2012) The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 15(2):137–146 84(

5. Kummar S, Kinders R, Gutierrez ME et al (2009) Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27(16):2705–2711

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid-liquid phase separation -related gene can predict prognosis and influence immune microenvironment in acute myeloid leukemia;2024-02-19

2. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy;Blood;2023-12-21

3. A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM);Journal of Neuro-Oncology;2023-11-28

4. A Multi-Site Phase I Trial of Veliparib with Standard Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM);2023-10-24

5. Myelotoxicity of Temozolomide Treatment in Patients with Glioblastoma Is It Time for a More Mechanistic Approach?;Cancers;2023-03-02